ES2176331T3 - Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia. - Google Patents

Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.

Info

Publication number
ES2176331T3
ES2176331T3 ES95924223T ES95924223T ES2176331T3 ES 2176331 T3 ES2176331 T3 ES 2176331T3 ES 95924223 T ES95924223 T ES 95924223T ES 95924223 T ES95924223 T ES 95924223T ES 2176331 T3 ES2176331 T3 ES 2176331T3
Authority
ES
Spain
Prior art keywords
pct
treatment
schisophrenia
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95924223T
Other languages
English (en)
Inventor
Meir Shinitzky
Michael Deckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2176331T3 publication Critical patent/ES2176331T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION HACE REFERENCIA A UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE TRASTORNOS ESQUIZOFRENICOS QUE INCLUYE UN VEHICULO ACEPTABLE FARMACEUTICAMENTE Y COMO INGREDIENTE ACTIVO UN AGENTE INMUNOSUPRESOR
ES95924223T 1994-06-13 1995-06-13 Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia. Expired - Lifetime ES2176331T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
ES2176331T3 true ES2176331T3 (es) 2002-12-01

Family

ID=11066236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95924223T Expired - Lifetime ES2176331T3 (es) 1994-06-13 1995-06-13 Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.

Country Status (11)

Country Link
US (1) US5912250A (es)
EP (1) EP0772442B1 (es)
JP (1) JPH10501257A (es)
AT (1) ATE216891T1 (es)
AU (1) AU704355B2 (es)
BR (1) BR9508021A (es)
CA (1) CA2192822C (es)
DE (1) DE69526584T2 (es)
ES (1) ES2176331T3 (es)
IL (1) IL110011A (es)
WO (1) WO1995034306A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020273A1 (en) * 1997-10-17 1999-04-29 The Rockefeller University Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) * 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
ES2685780T3 (es) 2002-08-22 2018-10-11 Sumitomo Dainippon Pharma Co., Ltd. Agente para el tratamiento de esquizofrenia
CN1826338B (zh) 2003-06-23 2011-07-13 大日本住友制药株式会社 老年性痴呆症治疗药
WO2005080976A1 (ja) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
DE69526584D1 (de) 2002-06-06
WO1995034306A1 (en) 1995-12-21
DE69526584T2 (de) 2002-11-14
EP0772442A1 (en) 1997-05-14
BR9508021A (pt) 2004-04-20
AU2881995A (en) 1996-01-05
CA2192822C (en) 2007-04-03
US5912250A (en) 1999-06-15
AU704355B2 (en) 1999-04-22
CA2192822A1 (en) 1995-12-21
ATE216891T1 (de) 2002-05-15
JPH10501257A (ja) 1998-02-03
IL110011A0 (en) 1994-10-07
IL110011A (en) 2004-09-27
EP0772442B1 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
DE59511002D1 (de) Wirkstoffe für die behandlung der senilen xerosis und zubereitungen
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
MY129356A (en) Electrospun pharmaceutical compositions
ECSP941122A (es) Derivados de 5-arilindoles
ES2094034T3 (es) Composicion antiacneica para el tratamiento simultaneo de las capas superficiales y profundas de la piel, su utilizacion.
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
MX9301197A (es) Derivados de indol.
TW324662B (en) Benzamide-containing pharmaceutical composition
FR2718020B1 (fr) Composition galénique mucoadhésive hétérofonctionnelle.
DE69432982D1 (de) Pour-on formulierung enthaltend polymerische material, glykole und glyzeriden
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
SE9702563D0 (sv) Compounds
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DK0713386T3 (da) Sprayformulering med kølende effekt
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
ES2157984T3 (es) Utilizacion de 4'-yodo-4'-desoxidoxorrubicina para el tratamiento de la amidoidosis.